Conexeu Sciences (NASDAQ: CNXU) director buys 166,666 shares and warrants

What happened

Conexeu Sciences Inc. (NASDAQ: CNXU) director and 10% owner Lynn Sebastian Purcell bought 166,666 shares at $3.00 each.

The purchase date was 10/15/2026, and the reported total was about $499,998.

The filing says each unit included one share of common stock and one warrant to buy one share at a $3.00 exercise price.

Those warrants were exercisable from 10/15/2026 to 10/15/2028.

After the transaction, Purcell reported beneficial ownership of 3,118,514 shares, held indirectly through OnePointTwo Capital Ventures II LLC.

The derivative table also shows 166,666 warrants acquired in the same transaction, with 574,058 warrants beneficially owned afterward.

The Form 4 ties the common shares and warrants to the same indirect ownership structure.

Key numbers

Metric	Latest	Change	Source
Shares bought	166,666 shares		SEC Form 4
Purchase price	$3.00 per share		SEC Form 4
Total purchase amount	about $499,998		SEC Form 4
Shares held after trade	3,118,514 shares		SEC Form 4
Purchase size as a share of pre-trade holding	5.6%		Calculated from SEC Form 4

Read more: Conexeu Sciences (CNXU) stock analysis and investment case

Why it matters

OptimistFi's case is that CNXU is a speculative, balance-sheet-backed med-tech option, and this filing strengthens that case modestly.

The 166,666 shares were about 5.6% of the holding before the trade, so the buy added to an already large indirect position rather than opening a new one.

Purcell is both a director and a 10% owner, so the trade carries governance weight.

The units also paired a share with a warrant at the same $3.00 purchase price, so the trade added optionality as well as equity exposure.

This is one insider purchase through an indirect holder, so it is a position update rather than evidence of operating progress.

It is still only one filing, so it shows conviction but not a broader pattern of buying.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Conexeu Sciences Inc.'s next quarterly report is the next scheduled update investors can compare with this Form 4.

Another reported increase in Purcell's stake would strengthen the signal, while an unchanged ownership line would leave this as a stand-alone purchase.

That follow-up will show whether this buy is part of continued accumulation or only a one-time addition to an existing position.

Until then, the Form 4 is the clearest dated evidence in the file on Purcell's current stake and transaction size.

More from OptimistFi

• CNXU stock: the Conexeu Sciences thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps